Global Alexipharmic Drugs Market, By Indication (Alcoholic Overdose, Opioid Overdose, Cyanide Poisoning, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Alexipharmic Drugs Market Analysis and Size
The global alexipharmic drugs market is expected to witness huge growth during the forecast period. The growth of the alexipharmic drugs market is accelerated by the rising cases of psychoactive substances abuse and increase dependency on narcotics drugs. Conversely, alternative treatments and the launch of new competitive drugs hamper the growth of the alexipharmic drugs market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global alexipharmic drugs market in the forecast period 2022-2029. The expected CAGR of global alexipharmic drugs market is tend to be around 5% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Alexipharmic drugs are a therapeutic agent which is commonly used as antidotes which neutralize or antagonize the unwanted as well as toxicant effect of poison, which the person intentionally or accidentally consumed. Many alexipharmic drugs act by preventing the formation of toxic metabolites or inhibiting toxicants' effect at the receptor binding site.
Alexipharmic Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Alcoholic Overdose, Opioid Overdose, Cyanide Poisoning, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Hope Pharmaceuticals (U.S.)
|
|
Market Opportunities
|
|
Global Alexipharmic Drugs Market Dynamics
Drivers
- Prevalence of Chronic Diseases
In 2018, around 51.8% of U.S. adults had at least one chronic condition, and around 27.2% had multiple chronic conditions. The prevalence was seen to be highest among women, adults aged 65 or older, and those living in rural areas. Thus, it boosts market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rising Adoption of Alcohol Consumption
According to the 2019 National Survey on Drug Use and Health (NSDUH), approximately 85.6 percent of people aged 18 years and above reported drinking alcohol at some point in their lifetime. In addition to this, the sedentary lifestyle and increasing stress compel the people for more consumption. Thus, all these factors enhance the market expansion.
- Increasing Demand for Retail Pharmacies
Rise in the number of renal drugs being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of alexipharmic drugs
The side effects associated with these drugs could curb the growth of the global alexipharmic drugs market over a forecast period. Excessive use of such drugs can lead to rashes, sleeplessness, vomiting, nausea, and several others, can hamper the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global alexipharmic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global alexipharmic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Alexipharmic Drugs Market
COVID-19 left a major impact on the global alexipharmic drugs market and even in the post pandemic situation, the market is expected to grow. Healthcare professionals had a huge responsibility to treat COVID-19 patients, which created a shift towards treating these chronic patients. This resulted in a shift in treating COVID-19 patients, thus boosting the market growth.
Global Alexipharmic Drugs Market Scope
The global alexipharmic drugs market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Alcoholic Overdose
- Opioid Overdose
- Cyanide Poisoning
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Alexipharmic Drugs Market Regional Analysis/Insights
The global alexipharmic drugs market is analysed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global alexipharmic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for global alexipharmic drugs market throughout the forecasted period due to the presence of refined healthcare infrastructure and large availability of treatment options.
North America dominates the market due to high incidence of poison cases and rise in research and development activities for alexipharmic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Alexipharmic Drugs Market Share Analysis
The global alexipharmic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global alexipharmic drugs market.
Key players operating in the global alexipharmic drugs market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
- Hope Pharmaceuticals (U.S.)
SKU-